ALTSGEYMER KASALLIGINI DAVOLASHDA ZAMONAVIY PATOGENETIK YONDASHUVLAR: TIZIMLI TAHLIL
Keywords:
Altsgeymer kasalligi, amiloid kaskad, tauopatiya, neyroinflamatsiya, xolinesteraza ingibitorlari, memantin, monoklonal antikorlar, lekanemab, donanemab, ARIA, multidomenli aralashuv, FINGER tadqiqotiAbstract
Ushbu maqolada Altsgeymer kasalligini davolashning patogenetik asoslangan zamonaviy usullari tizimli tahlil qilingan. Kasallik patogenezining asosiy mexanizmlari — amiloid kaskad, tauopatiya va neyroinflamatsiya yoritilgan. An’anaviy simptomatik terapiya (xolinesteraza ingibitorlari, memantin) va patogenetik terapiya (amiloidga qarshi monoklonal antikorlar: lekanemab, donanemab, adukanumab) ning klinik samaradorligi hamda xavfsizlik profili baholangan. Neyroinflamatsiyani modulyatsiya qiluvchi strategiyalar, modifikatsiyalovchi omillar (yurak-qon tomir xavf omillarini korreksiyalash, turmush tarzi aralashuvlari) va kombinatsiyalangan terapiya istiqbollari tahlil qilingan. Maqola Altsgeymer kasalligini davolashda mavjud imkoniyatlar va kelajakdagi tadqiqot yoʻnalishlarini yoritishga qaratilgan.
References
1. Hardy J., Selkoe D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297(5580), 353-356.
2. Rogers S.L. et al. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50(1), 136-145.
3. Reisberg B. et al. (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med, 348(14), 1333-1341.
4. Tariot P.N. et al. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA, 291(3), 317-324.
5. Birks J.S. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, (1), CD005593.
6. ADAPT Research Group (2007). Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology, 68(21), 1800-1808.
7. Sperling R.A. et al. (2012). Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab. Neurology, 78(13), 956-961.
8. Dysken M.W. et al. (2014). Effect of vitamin E and memantine on functional decline in Alzheimer disease. JAMA, 311(1), 33-44.
9. Rebok G.W. et al. (2014). Ten-year effects of the ACTIVE cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc, 62(1), 16-24.
10. Heneka M.T. et al. (2015). Neuroinflammation in Alzheimer's disease. Lancet Neurol, 14(4), 388-405.
11. Butchart J. et al. (2015). Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind phase 2 trial. Neurology, 84(21), 2161-2168.
12. Morris M.C. et al. (2015). MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement, 11(9), 1007-1014.
13. Ngandu T. et al. (2015). A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). Lancet, 385(9984), 2255-2263.
14. Gejl M. et al. (2016). Liraglutide alters cognitive function and brain activity in patients with type 2 diabetes and Alzheimer's disease. Diabetes, 65(Suppl 1), A14.
15. Iqbal K. et al. (2016). Tau in Alzheimer's disease: mechanisms and therapeutic strategies. Curr Alzheimer Res, 13(3), 271-283.
16. Olmos-Alonso A. et al. (2016). Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. Brain, 139(Pt 3), 891-907.
17. Jack C.R. et al. (2018). NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement, 14(4), 535-562.
18. Gratuze M. et al. (2018). TREM2 in Alzheimer's disease: a new player in the field. Mol Neurodegener, 13(1), 30.
19. Long J.M., Holtzman D.M. (2019). Alzheimer disease: an update on pathobiology and treatment strategies. Cell, 179(2), 312-339.
20. Yamazaki Y. et al. (2019). Apolipoprotein E and Alzheimer's disease: pathobiology and targeting strategies. Nat Rev Neurol, 15(9), 501-518.
21. Erickson K.I. et al. (2019). Physical activity and cognition in older adults. Exerc Sport Sci Rev, 47(3), 140-147.
22. Williamson J.D. et al. (2019). Effect of intensive vs standard blood pressure control on probable dementia (SPRINT MIND). JAMA, 321(6), 553-561.
23. Kivipelto M. et al. (2020). World-Wide FINGERS network: a global approach to risk reduction and prevention of dementia. Alzheimers Dement, 16(7), 1078-1094.
24. Knopman D.S. et al. (2021). Aducanumab: appropriate use recommendations. Neurology, 97(17), 1-13.
25. van Dyck C.H. et al. (2023). Lecanemab in early Alzheimer's disease. N Engl J Med, 388(1), 9-21.
26. Sims J.R. et al. (2023). Donanemab in early symptomatic Alzheimer's disease (TRAILBLAZER-ALZ 2). JAMA, 330(6), 512-527.
27. Cummings J. et al. (2023). Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement, 9(2), e12385.
